Corvus Pharmaceuticals, Inc.
CRVSNasdaqHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Operating income | −$43.0M | −$27.5M | −$23.4M | −$32.6M | −$38.6M | −$43.8M |
| Net income | −$15.3M | −$62.3M | −$27.0M | −$41.3M | −$43.2M | −$6.0M |
| Total assets | $71.1M | $68.9M | $45.6M | $68.2M | $109.5M | $85.5M |
| Total liabilities | $9.9M | $36.3M | $6.9M | $12.1M | $12.3M | $13.4M |
| Equity | $61.2M | $32.6M | $38.7M | $56.1M | $97.2M | $72.1M |
| EPS (diluted) | $-0.53 | $-1.02 | $-0.56 | $-0.89 | $-1.03 | $-0.20 |
| Shares out. | 68.1M | 49.0M | 46.6M | 46.6M | 38.3M | 29.3M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- —
- Net margin
- —
- Return on equity
- −25.0%
- Return on assets
- −21.5%
- Return on capital (ROCE)
- −69.6%
- Liabilities / assets
- 13.9%
- Debt / equity
- 0.16×
- Book value / share
- $0.90
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -11.97distress
- Accruals / assets
- 24.6%high accruals
- Piotroski F-Score
- 3/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 1 severe● 2 warning● 1 good- Altman Z″ in the distress zone
- Negative operating cash flow
- High accruals — earnings-quality risk
- Conservative leverage (liabilities < 50% of assets)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 1Active Not Recruitingreadout ~2026-04-30A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma
- Phase 2Recruitingreadout ~2027-06Study to Evaluate Soquelitinib in Participants With Moderate to Severe AD
- Phase 3Recruitingreadout ~2027-11Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Miller Richard A MdOfficer — President and CEO | May 18, 2026 | Buy | 5,000 | $12.05 |
| Thompson Peter A.Director | Jan 28, 2026 | Option exercise | 30,000 | $15.00 |
| Orbimed Advisors LlcDirector | Jun 27, 2025 | Option exercise | 1.4M | $3.50 |
| Thompson Peter A.Director | Jun 27, 2025 | Option exercise | 1.4M | $3.50 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 18.9M | 12.0 | +2.9% |
| Apr 30, 2026 | 18.4M | 11.5 | +8.6% |
| Apr 15, 2026 | 16.9M | 21.8 | -0.1% |
| Mar 31, 2026 | 17.0M | 11.1 | +5.6% |
| Mar 13, 2026 | 16.1M | 14.7 | +0.3% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Regulation FD disclosure · Other material eventMay 14, 2026
- Results of operationsMay 7, 2026
- Director / officer changeApr 23, 2026
- Entered a material agreementMar 13, 2026
- Results of operationsMar 12, 2026
- Other material eventJan 23, 2026
- Other material eventJan 20, 2026
- Regulation FD disclosure · Other material eventJan 20, 2026
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 4May 20, 2026
- SCHEDULE 13G/AMay 15, 2026
- SCHEDULE 13GMay 15, 2026
- 8-KFORM 8-KMay 14, 2026
- S-8FORM S-8May 7, 2026
- 10-QMay 7, 2026
- 8-KFORM 8-KMay 7, 2026
- 4Apr 27, 2026
- 3Apr 27, 2026
- SCHEDULE 13G/AApr 27, 2026
- DEFA14AApr 24, 2026
- DEF 14AApr 24, 2026
- 8-KApr 23, 2026
- SCHEDULE 13G/AMar 26, 2026
- 8-KFORM 8-KMar 13, 2026
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.